Results 171 to 180 of about 14,319 (272)
Platelet-derived growth factor-dependent association of the GTPase-activating protein of Ras and Src [PDF]
, 1999 Thomas K. SCHLESINGER +3 more
openalex +1 more source
Small‐Molecule KRAS Inhibitors by Tyrosine Covalent Bond Formation
ChemMedChem, Accepted Article.The development of the KRAS G12C inhibitor sotorasib was a major advance towards drugging KRAS. However, the G12C mutation is only found in about 10% of tumors with a KRAS mutation. KRAS tyrosine amino acids could provide alternative sites for covalent drug development.
Alexander Landgraf +5 more
wiley +1 more source
Characterization of the C. elegans gap‐2 gene encoding a novel Ras‐GTPase activating protein and its possible role in larval development [PDF]
, 1998 Seiji Hayashizaki +2 more
openalex +1 more source
Nondegradative Synthetic Molecular Glues Enter the Clinic
ChemMedChem, EarlyView.Proximity‐inducing drugs are a novel therapeutic modality and currently mainly focused on target degradation. Recently, nondegradative molecular glues, inspired by natural products that reprogram cyclophilin A (Cyp A) to inhibit K‐Ras, have entered the clinic.
Maximilian L. Repity +2 more
wiley +1 more source
A little less aggregation a little more replication: Viral manipulation of stress granules
WIREs RNA, Volume 14, Issue 1, January/February 2023., 2023 Viruses depend entirely on host machinery and therefore aim to conquer the host and defeat its defenses to co‐opt its resources for its own replication. Improved understanding of how viruses counteract host immune responses such as stress granule assembly, detailed here, will inform future antiviral therapeutic strategies.
Matthew J. Brownsword, Nicolas Locker
wiley +1 more source
Identification of the Ras GTPase-activating protein GAP1m as a phosphatidylinositol-3,4,5-trisphosphate-binding protein in vivo [PDF]
, 1999 Peter J. Lockyer +5 more
openalex +1 more source